Research Article
Cervical Cancer Staging in Saudi Arabia Clinico-radiological Correlation

Nisreen Anfinan
Gynecology Oncology Unit, Department of Obstetrics and Gynaecology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

Correspondence should be addressed to Nisreen Anfinan; dr_nisreen2001@yahoo.com

Received 28 November 2018; Revised 1 April 2019; Accepted 10 June 2019; Published 23 June 2019

Academic Editor: Enzo Terreno

Copyright © 2019 Nisreen Anfinan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. The aim of this study was to compare the finding of pelvic MRI with clinical staging using cystoscopy and sigmoidoscopy for cervical cancer patients.

Method. We reviewed all patients with cervical cancer between January 2001 and December 2015. We correlate the clinicalexamination, cystoscopy, and sigmoidoscopy with MRI findings.

Result. A total of 152 patients were enrolled. 114 (74.9%) were with locally advanced cervix cancer. The true positives for MRI in the detection of parametrium were in 94 patients, with sensitivity, specificity, positive, PPV, and NPV of 72%, 82%, 96%, and 33%, respectively. The false negative of the MRI to detect the bladder invasion was 2. Nineteen patients reported having bladder invasion on MRI not confirmed by cystoscopy. None of the patients who had a negative rectal invasion by MRI were found to have rectal involvement by sigmoidoscopy with a specificity of 91%.

Conclusion. The combined MRI and clinical staging for parametrial evaluation should still be carried out for the staging of cervical cancer. However, in the absence of the bladder and the rectal invasion in the MRI, it will be safe to avoid the need for a cystoscopy and/or sigmoidoscopy for complete staging in the majority of patients with cervical cancer.

1. Introduction

The precise tumor staging in patients with cervical cancer is crucial for an appropriate therapy. Traditionally, cervical cancer staging is performed with a pelvic clinical examination that includes inspection and palpation (if necessary under anesthesia) with special consideration to tumor size, vaginal involvement, and parametral and pelvic sidewall status, as well as cystoscopy, sigmoidoscopy, intravenous urography (IVU), and radiological evaluation of the lung [1]. Staging of cervical cancer is executed in compliance with the guidelines established by the International Federation of Gynecology and Obstetrics (FIGO) reviewed in 2009 [2]. In case of tumor being clinically limited to the cervix (≤ stage IIA), the preferred treatment is surgery in most patients. When the tumor extends clinically to the parametrium (late stage ≥ stage IIB), primary chemoradiation is the treatment of choice [1, 3, 4]. However, clinical staging is subject to inaccuracy with high error rates ranging between 26 and 66% [5–10].

It has been shown that magnetic resonance imaging (MRI) is a reliable investigation to assess the tumor invasiveness and may provide accurate staging for cervical cancer [3, 9, 11–13].

We carried out this study to present our experience with the use of MRI in the staging of patients with cervical cancer with reference to the standard clinical examination with respect to local pelvic involvement, as well as bladder and rectal invasion.

2. Material and Methods

We conducted a retrospective review of all histologically confirmed cases of cervical cancer who were treated at King Abdulaziz University Hospital, Jeddah, Saudi Arabia, in the period from January 2001 to December 2015. There were 152 patients who completed their final stage through the standard clinical examination and the MRI pelvis. Data were collected, including age, parity, and the clinical and MRI findings. The staging was carried out according to the FIGO staging system [2].

We correlated the MRI finding with respect to the vagina, parametrium, and pelvic side wall involvement as well as
bladder and rectal involvement of 152 patients with the standard clinical examination under anesthesia, cystoscopy, and sigmoidoscopy.

Sensitivity, specificity, and negative (NPV) and positive (PPV) predictive values were computed using the SPSS software program.

3. Result

The population’s median age was 53 years (range: 20-90 years). The median parity was four with a range between 0 and 14. The median BMI was 26.6 (range 14.8-45.4). Of the total patients, 17 (11.2%) were stage IB and 114 (74.9%) were at locally advanced stage of cervix cancer. Bladder involvement was found among 11 (7.2%) patients and distal metastasis was found in 10 (6.6%) (Table 1).

The most common histopathological type was squamous cell carcinoma in 128 (84.2%), followed by adenocarcinoma in 20 (13.4%) of the patients. Two patients were with adenosquamous carcinoma and one was with leiomyosarcoma and non-Hodgkin’s lymphoma was in the other patient (Table 2).

The correlation between MRI and the standard clinical examination is depicted in Table 3.

The vagina was involved in 17 cases, as identified by clinical examination but not observed in MRI with the sensitivity of 67% and the specificity of 60%. The number of true positives of MRI findings in the detection of parametrium was 94, resulting in sensitivity 72%, specificity 82%, PPV 96%, and NPV 33%.

The specificity of MRI to detect pelvic sidewall disease was 94% with PPV 77%. Regarding detection of bladder invasion, MRI yielded 2 false negatives and 19 patients, who were positively detected by MRI, were not confirmed by cystoscopy, with sensitivity of 78%, specificity 87%, and NPV 98%.

None of the patients who had a negative rectal invasion by MRI was found to have rectal involvement by sigmoidoscopy with a specificity of 91%.

4. Discussion

There are numerous prognostic factors that predict the outcome of cervical cancer and can affect treatment planning. Tumor histopathology is an important prognostic factor; and squamous cell carcinoma represents the most frequent histopathological type in this study. Other reports revealed similar incidence rates between 80 and 90% [14]. The tumor stage constitutes an additional prognostic factor [15]. Similar to what has been reported in Saudi Arabia by Manji in 1998 [16], our study showed that 88.8% were diagnosed at an advanced stage using FIGO clinical staging; this was due to lack of cervical screening program in Saudi Arabia.

Parametrial invasion is considered a determining factor for appropriate treatment choice, commonly surgery or radiotherapy. MRI diagnostic performance showed high NPV of 94-100%, indicating its high reliability in excluding parametrial invasion [7, 17]. Other studies reported that MRI has 69% and 93% sensitivity and specificity, respectively, to detect parametral invasion [18, 19]. In our study population, MRI had a sensitivity of 72%, but specificity was 82%. Only four false positive findings occurred with MRI, while it failed to detect parametrial involvement in 36 patients resulting in very low NPV of 33%.

MRI performance in detecting vaginal invasion is reported to be adequate, with a general accuracy of 86%-93% [20, 21]. We observed a slight decrease in accuracy with a sensitivity of 67% and a positive predictive value of 47%.

The reported sensitivity and specificity of MRI in detecting the bladder and rectum invasion are 71%-100% and 88%-91%, respectively [22, 23]. Bladder and rectal involvement can be confidently excluded in MRI with 100% NPV, making cystoscopy and sigmoidoscopy redundant [22]. In our study, the bladder NPV and rectal invasion are 98%-100%, respectively, which support the previous finding. We also found that, in our experience, the MRI did not detect bladder invasion in two patients and 19 patients who reported having bladder invasion on MRI were not confirmed by cystoscopy, which means that the MRI can replace the cystoscopic examination for the evaluation of the bladder. However, this must be determined by further study.

In conclusion, the majority of cervical cancer patients in our study population were diagnosed at an advanced stage. There was discrepancy between the MRI finding and the clinical examination for the evaluation of vaginal and parametral involvement, and that is why combined MRI and clinical staging are still required for adequate evaluation of parametral and vaginal invasion. In absence of MRI evidence of bladder and rectal invasion, performing cystoscopy and/or sigmoidoscopy for complete staging can be safely waived in majority of cervical cancer patients.

Limitations of the Study. Our study involved small number of patients and the correlation was limited, since we did not have histopathological confirmation of the parametrium and vagina invasion, which is not required by FIGO staging.
Table 3: Correlation between Clinical Staging and MRI finding in cervical cancer patients.

| MR imaging          | True positives | A number of: |         | Sensitivity (95% CI) | Specificity (95% CI) | Positive predictive value (95% CI) | Negative predictive value (95% CI) |
|---------------------|----------------|--------------|---------|---------------------|----------------------|-------------------------------------|-----------------------------------|
|                     |                | False positives | False Negatives | True Negatives |                     |                                     |                                   |
| Parametrial         | 94             | 4            | 36       | 18                  | 0.72 (0.65 – 0.8)    | 0.82 (0.66 – 0.96)               | 0.96 (0.92-1)                    | 0.33 (0.21-0.46)                 |
| Pelvic Side Wall    | 23             | 7            | 18       | 104                 | 0.56 (0.41 – 0.71)   | 0.94 (0.89 – 0.98)               | 0.77 (0.62-0.92)                 | 0.85 (0.79-0.92)                 |
| Bladder invasion    | 7              | 19           | 2        | 122                 | 0.78 (0.5 – 1)       | 0.87 (0.8 – 0.92)                | 0.27 (0.1-0.44)                  | 0.98 (0.96-1)                    |
| Rectal invasion     | 1              | 8            | 0        | 140                 | 0.75 (0.13 – 0.15)   | 0.91 (0.98 – 1)                  | 0.15 (0.00-0.37)                 | 0.99 (0.99-1)                    |
| Vaginal involvement | 34             | 38           | 17       | 56                  | 0.67 (0.54-0.8)      | 0.6 (0.5-0.7)                    | 0.47 (0.4-0.6)                   | 0.77 (0.67-0.86)                 |
Data Availability
The data used to support the findings of this study are available from the corresponding author upon request.

Disclosure
This paper has been presented as a poster in 17th Biennial Meeting of the International Gynecologic Cancer Society as well as XXII FIGO 2018 with interim finding.

Conflicts of Interest
The authors declare having no financial or other conflicts regarding the preparation and dissemination of this paper.

Acknowledgments
Special thanks are due to Professor Ezz Abdelfattah for the public or private, profitable or not-for-profit sector.

References
[1] J. Benedet, H. Bender, H. Jones, H. Y. Ngan, and S. Pecorelli, “FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers,” FIGO Committee on Gynecologic Oncology: International Journal of Gynecology & Obstetrics, vol. 70, no. 2, pp. 209–262, 2000.
[2] S. Pecorelli, L. Zigliani, and F. Odicino, “Revised FIGO staging for carcinoma of the cervix,” International Journal of Gynecology and Obstetrics, vol. 105, no. 2, pp. 107–108, 2009.
[3] E. A. Boss, J. O. Barentsz, L. F. A. G. Massuger, and H. Boonstra, “The role of MR imaging in invasive cervical carcinoma,” European Radiology, vol. 10, no. 2, pp. 256–270, 2000.
[4] F. Joly-Lobbedez, “Evidence based of chemoradiotherapy in cervix carcinoma,” Cancer Radiothérapie, vol. 13, no. 6–7, pp. 503–506, 2009.
[5] H. E. Averette, J. H. Ford Jr., R. C. Dudan, R. E. Girtanner, W. J. Hoskins, and M. H. Lutz, “Staging of cervical cancer,” Clinical Obstetrics and Gynecology, vol. 18, no. 3, pp. 215–232, 1975.
[6] T. W. Griffin, R. G. Parker, and W. J. Taylor, “An evaluation of procedures used in staging carcinoma of the cervix,” American Journal of Roentgenology, vol. 127, no. 5, pp. 825–827, 1976.
[7] S. H. Kim, B. I. Choi, H. P. Lee et al., “Uterine cervical carcinoma: Comparison of CT and MR findings,” Radiology, vol. 175, no. 1, pp. 45–51, 1990.
[8] C. Ho, T. Chien, C. Jeng, Y. Tsang, B. Shih, and S. Chang, “Staging of cervical cancer: comparison between magnetic resonance imaging, computed tomography and pelvic examination under anesthesia,” Journal of the Formosan Medical Association, vol. 91, no. 10, pp. 982–990, 1992.
[9] S. Bipat, A. S. Glas, J. Van Der Velden, A. H. Zwinderman, P. M. M. Bossuyt, and J. Stoker, “Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: A systematic review,” Gynecologic Oncology, vol. 91, no. 1, pp. 59–66, 2003.
[10] P. Bhosale, S. Peungjesada, C. Devine, A. Balachandran, and R. Iyer, “Role of magnetic resonance imaging as an adjunct to clinical staging in cervical carcinoma,” Journal of Computer Assisted Tomography, vol. 34, no. 6, pp. 855–864, 2010.
[11] K. Narayan, “Arguments for a magnetic resonance imaging-assisted FIGO staging system for cervical cancer,” International Journal of Gynecologic Cancer, vol. 15, no. 4, pp. 573–582, 2005.
[12] R. C. Smith, C. Reinhold, T. R. McCauley et al., “Multicoil high-resolution fast spin-echo MR imaging of the female pelvis,” Radiology, vol. 184, no. 3, pp. 671–675, 1992.
[13] R. Mezrich, “Magnetic resonance imaging applications in uterine cervical cancer,” Magnetic Resonance Imaging Clinics of North America, vol. 2, no. 2, pp. 211–243, 1994.
[14] C. K. Chung, W. A. Nahhas, R. Zaino, J. A. Stryker, and R. Mortel, “Histologic grade and lymph node metastasis in squamous cell carcinoma of the cervix,” Gynecologic Oncology, vol. 12, no. 3, pp. 348–354, 1981.
[15] H. Hricak, J. M. Quivey, Z. Campos et al., “Carcinoma of the cervix: Predictive value of clinical and magnetic resonance (mr) imaging assessment of prognostic factors,” International Journal of Radiation Oncology • Biology • Physics, vol. 27, no. 4, pp. 791–801, 1993.
[16] M. Manjii, D. Pradhan, M. El-Senoussi et al., “Carcinoma of cervix, the King Faisal Specialist Hospital & Research Center experience—the need for screening for cervical cancer in developing countries,” European Journal of Gynaecological Oncology, vol. 20, no. 5–6, pp. 412–415, 1999.
[17] T. Hayashi and T. Kato, “Usefulness of tumor size on MR imaging in assessing the prognosis of uterine cervical cancer treated with radiation,” Nihon Igaku Hoshasen Gakkai Zasshi, vol. 59, no. 6, pp. 250–255, 1999.
[18] L. E. Subak, H. Hricak, C. B. Powell, E. Azizi, and J. L. Stern, “Cervical carcinoma: Computed tomography and magnetic resonance imaging for preoperative staging,” Obstetrics & Gynecology, vol. 86, no. 1, pp. 43–50, 1995.
[19] M.-H. Sheu, C.-Y. Chang, J.-H. Wang, and M.-S. Yen, “MR staging of clinical stage I and IIa cervical carcinoma: A reappraisal of efficacy and pitfalls,” European Journal of Radiology, vol. 38, no. 3, article no. 1816, pp. 225–231, 2001.
[20] E. Sala, S. Wakely, E. Senior, and D. Lomas, “MRI of malignant neoplasms of the uterine corpus and cervix,” American Journal of Roentgenology, vol. 188, no. 6, pp. 1577–1587, 2007.
[21] H. Hricak, C. B. Powell, K. K. Yu et al., “Invasive cervical carcinoma: the role of MR imaging in pretreatment work-up: cost minimization and diagnostic efficacy analysis,” Radiology, vol. 198, no. 2, pp. 403–409, 1996.
[22] A. G. Rockall, S. Ghosh, F. Alexander–Sefre et al., “Can MRI rule out bladder and rectal invasion in cervical cancer to help select patients for limited EUA?” Gynecologic Oncology, vol. 101, no. 2, pp. 244–249, 2006.
[23] W. Kim, S. Chang, K. Chang, S. Yoo, E. Lee, and H. Ryu, “Reliability of magnetic resonance imaging for bladder or rectum invasion in cervical cancer,” The Journal of Reproductive Medicine, vol. 56, no. 11-12, pp. 485–490, 2011.